Abstract

BackgroundImmunosuppressive agents in general are shown to prevent renal progression and all-cause mortality in idiopathic membranous nephropathy (IMN) patients with nephrotic syndrome. However, the efficacy and safety of different immunosuppressive treatments have not been systematic assessed and compared. A network meta-analysis was performed to compare different immunosuppressive treatment in IMN.MethodsCochrane library, MEDLINE, EMBASE and trial register system were searched for randomized controlled trials reporting the treatments for IMN to May 3, 2016. Composite endpoint of mortality or end-stage kidney disease (ESKD), complete or partial proteinuria remission and withdrawal because of treatment adverse events were compared combing direct and indirect comparison using network meta-analysis. Ranking different immunosuppressive treatments in the outcomes were analyzed by using surface under the cumulative ranking curve (SUCRA).ResultsTotal 36 randomized controlled trials (n = 2018) covering 11 kinds of treatments were included. Compared with non-immunosuppressive treatment, only cyclophosphamide (CTX) and chlorambucil significantly reduced the risk of composite outcome of mortality or ESKD while combining the direct and indirect comparison (OR = 0.31, 95%CI: 0.12–0.81 and OR = 0.33, 95%CI: 0.12–0.92). CTX increased the composite outcome of complete remission (CR) or partial remission (PR) (OR = 4.29, 95%CI: 2.30–8.00) but chlorambucil did not (OR = 1.58, 95%CI: 0.80–3.12) as compared with non-immunosuppressive treatment. Chlorambucil also significantly increased the withdrawal risk (OR = 3.34, 95%CI: 1.37–8.17) as compared to CTX. Both tacrolimus (OR = 3.10, 95%CI: 1.36–7.09) and cyclosporine (CsA) (OR = 2.81, 95%CI: 1.08–7.32) also significantly increased the rate of CR or PR as compared with non-immunosuppressive treatment (without significant difference as compared with CTX), while ranking results showed that cyclosporine or tacrolimus was with less possibility of drug withdrawal as compared to CTX.ConclusionsCyclophosphamide and chlorambucil reduce risk of ESKD or death in IMN with nephrotic range proteinuria, but carry substantial toxicity that may be lower for cyclophosphamide. Tacrolimus and cyclosporine increase the possibility of proteinuria remission with less drug withdrawal, but the effects on kidney failure remain uncertain.

Highlights

  • Idiopathic membranous nephropathy (IMN) is one of the commonest causes of primary nephrotic syndrome in adults [1]

  • Compared with non-immunosuppressive treatment, only cyclophosphamide (CTX) and chlorambucil significantly reduced the risk of composite outcome of mortality or end-stage kidney disease (ESKD) while combining the direct and indirect comparison (OR = 0.31, 95%confidence intervals (CI): 0.12–0.81 and Odds ratios (OR) = 0.33, 95%CI: 0.12–0.92)

  • CTX increased the composite outcome of complete remission (CR) or partial remission (PR) (OR = 4.29, 95%CI: 2.30–8.00) but chlorambucil

Read more

Summary

Introduction

Idiopathic membranous nephropathy (IMN) is one of the commonest causes of primary nephrotic syndrome in adults [1]. The remaining third of patients will progress to end-stage kidney disease (ESKD), and the risk is higher in people with nephrotic range proteinuria [2,3]. Immunosuppressive therapy has been suggested to reduced proteinuria, all-cause mortality and progression to ESKD [4]. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend steroids plus alkylating agents in patients at high risk of developing ESKD based on severe proteinuria. People with contraindications for alkylating agents or who do not tolerant them, are recommended to receive steroids plus calcineurin inhibitors, (such as tacrolimus and cyclosporine) as second line therapy[5]. Immunosuppressive agents in general are shown to prevent renal progression and allcause mortality in idiopathic membranous nephropathy (IMN) patients with nephrotic syndrome. A network meta-analysis was performed to compare different immunosuppressive treatment in IMN

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call